Pharvaris to Participate in Upcoming April Investor Conferences
Pharvaris (Nasdaq: PHVS), a clinical-stage company specializing in oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), announced its participation in two investor conferences in April 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS), a clinical-stage company specializing in oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), announced its participation in two investor conferences in April 2022. The 21st Annual Needham Virtual Healthcare Conference will take place on April 11, 2022, at 2:45 PM CEST, while the Kempen 14th Life Sciences Conference is scheduled for April 21, 2022, at 3:00 PM CEST in Amsterdam. Investors can access webcasts of the presentations on the company's website, with replays available for 30 days post-event.
Details
News Market Reaction – PHVS
The recorded move for PHVS in the trading session of this news was +1.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, April 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that management will participate in two upcoming investor conferences in April:
21st Annual Needham Virtual Healthcare Conference
Format: Virtual Presentation
Date/Time: Monday, April 11, 2022 at 2:45 PM CEST (8:45 AM EDT)
Location: Virtual
Kempen 14th Life Sciences Conference
Format: In-Person Presentation
Date/Time: Thursday, April 21, 2022 at 3:00 PM CEST (9:00AM EDT)
Location: Amsterdam, Netherlands
A webcast of the presentations will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following each presentation.
About Pharvaris
Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE more effective and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.
Pharvaris
Maryann Cimino
Director of Corporate Relations
+1-617-710-7305
maryann.cimino@pharvaris.com
Investor Contact
Sarah McCabe
Stern Investor Relations, Inc.
+1-212-362-1200
sarah.mccabe@sternir.com
Media Contact
Maggie Beller
Russo Partners, LLC
+1-646-942-5631
maggie.beller@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.